See more : Jenn Feng Industrial Co., Ltd. (1538.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Skye Bioscience, Inc. (SKYE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Skye Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Weifu High-Technology Group Co., Ltd. (000581.SZ) Income Statement Analysis – Financial Results
- CompoSecure, Inc. (CMPOW) Income Statement Analysis – Financial Results
- AMCON Distributing Company (DIT) Income Statement Analysis – Financial Results
- Rexel S.A. (RXL.PA) Income Statement Analysis – Financial Results
- AfriTin Mining Limited (AFTTF) Income Statement Analysis – Financial Results
Skye Bioscience, Inc. (SKYE)
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 339.93K | 16.24K |
| Cost of Revenue | 124.25K | 115.00K | 34.13K | 1.87K | 1.46K | 1.54K | 8.04K | 14.92K | 9.95K | 0.00 | 131.34K | 5.36K |
| Gross Profit | -124.25K | -115.00K | -34.13K | -1.87K | -1.46K | -1.54K | -8.04K | -14.92K | -9.95K | 0.00 | 208.59K | 10.89K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 61.36% | 67.03% |
| Research & Development | 5.82M | 6.01M | 2.93M | 1.94M | 2.24M | 329.97K | 311.30K | 939.04K | 576.09K | 227.50K | 0.00 | 0.00 |
| General & Administrative | 7.85M | 6.09M | 4.92M | 4.34M | 4.39M | 4.36M | 3.55M | 3.53M | 3.74M | 2.50M | 120.40K | 6.37K |
| Selling & Marketing | -124.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.73M | 6.09M | 4.92M | 4.34M | 4.39M | 4.36M | 3.55M | 3.53M | 3.74M | 2.50M | 120.40K | 6.37K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 102.85K | -48.56K | -1.00M | 0.00 | 67.30K | 396.00 |
| Operating Expenses | 13.55M | 12.11M | 7.85M | 6.29M | 6.63M | 4.69M | 3.86M | 4.47M | 4.32M | 2.73M | 120.40K | 6.77K |
| Cost & Expenses | 13.67M | 12.11M | 7.85M | 6.29M | 6.63M | 4.69M | 3.86M | 4.47M | 4.32M | 2.73M | 120.40K | 12.13K |
| Interest Income | 99.97K | 19.01K | 3.00 | 29.00 | 26.00 | 84.00 | 0.00 | 0.00 | 0.00 | 0.00 | 789.00 | 638.00 |
| Interest Expense | 906.27K | 665.13K | 767.51K | 706.39K | 987.80K | 94.76K | 667.00 | 0.00 | 522.34K | 0.00 | 2.15K | 638.00 |
| Depreciation & Amortization | 124.25K | 115.00K | 34.13K | 1.87K | 1.46K | 1.54K | 8.04K | 14.92K | 9.95K | 1.91K | 16.48K | 638.00 |
| EBITDA | -13.55M | -12.09M | -7.81M | -6.29M | 2.04M | -4.69M | -3.85M | 0.00 | 0.00 | 0.00 | -7.24K | 4.76K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35.42% | 29.27% |
| Operating Income | -13.67M | -18.31M | -7.85M | -6.29M | -6.63M | -4.69M | -3.86M | -4.47M | -4.32M | -2.73M | -120.40K | 4.12K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35.42% | 25.35% |
| Total Other Income/Expenses | -23.97M | -7.37M | -672.37K | -270.09K | 7.69M | -14.50M | 766.53K | 1.29M | -522.34K | 0.00 | 3.46K | 638.00 |
| Income Before Tax | -37.64M | -19.47M | -8.52M | -6.56M | 1.05M | -19.19M | -3.09M | -3.18M | -4.84M | -2.73M | -3.78K | 4.76K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.11% | 29.27% |
| Income Tax Expense | 3.60K | 6.74K | 2.10K | 1.60K | 1.60K | 1.64K | 1.60K | 1.60K | 1.72K | 2.51K | -3.46K | 246.00 |
| Net Income | -37.64M | -19.48M | -8.52M | -6.56M | 1.05M | -19.19M | -3.09M | -3.18M | -4.84M | -2.73M | -120.40K | 4.51K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35.42% | 27.76% |
| EPS | -5.37 | -9.82 | -5.24 | -6.39 | 1.98 | -36.51 | -25.62 | -41.93 | -71.45 | -65.08 | -3.52 | 0.13 |
| EPS Diluted | -5.37 | -9.82 | -5.15 | -6.39 | 1.98 | -36.51 | -25.62 | -39.90 | -70.93 | -65.08 | -3.52 | 0.13 |
| Weighted Avg Shares Out | 7.01M | 1.98M | 1.63M | 1.03M | 532.01K | 525.78K | 120.77K | 75.79K | 67.75K | 42.01K | 34.21K | 34.21K |
| Weighted Avg Shares Out (Dil) | 7.01M | 1.98M | 1.65M | 1.03M | 532.01K | 525.78K | 120.77K | 79.65K | 68.25K | 42.01K | 34.21K | 34.21K |
Did Skye Bioscience, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SKYE
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on...
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE)
NEW YORK, NY / ACCESSWIRE / August 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE)
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Skye Bioscience, Inc. (SKYE) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports